On November 15, 2019 Aptorum Group Limited (Nasdaq: APM) ("the Company") a biopharmaceutical company focused on the development of novel therapeutics to address certain global unmet medical needs, reported the results of its 2019 Annual General Meeting, which was held on November 14, 2019, in Hong Kong (Press release, Aptorum, NOV 15, 2019, View Source [SID1234551382]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the Annual General Meeting, shareholders

re-elected all of the Company’s current directors, namely Mr. Ian Huen, Mr. Darren Lui, Dr. Clark Cheng, Dr. Justin Wu, Mr. Charles Bathurst, Dr. Mirko Scherer and Professor Douglas Arner as directors of the Company until the Company’s 2020 annual general meeting or until their respective successors are duly appointed and qualified; and
approved, ratified and confirmed the re-appointment of Marcum Bernsteun & Pinchuk LLP as the Company’s independent auditors for the year ending December 31, 2019 and authorized the Board of Directors to fix the remuneration of the auditors.